Turoctocog alfa is safe for the treatment of Indian patients with hemophilia A: Guardian 10 trial results.

ABSTRACT:

Background

Hemophilia A is an X chromosome-linked bleeding disorder caused by the deficiency of coagulation factor VIII (FVIII). The majority of the Indian population with hemophilia A use plasma-derived clotting factors and, in some instances, fresh frozen plasma and cryoprecipitate. Safer and more efficient treatment options are needed for this group of patients.

Objectives

To assess the safety of turoctocog alfa, a third-generation recombinant FVIII molecule, for the treatment and prophylaxis of bleeding episodes in previously treated Indian patients with moderate or severe hemophilia A.

Patients/methods

This single-country, multicenter, open-label, nonrandomized trial enrolled 60 patients who received prophylactic treatment with turoctocog alfa for 8 weeks, which

SUBMITTER: John MJ 

PROVIDER: S-EPMC7695559 | biostudies-literature | 2020 Nov

REPOSITORIES: biostudies-literature